Checkmate Pharmaceuticals, Inc.
CMPIDelisted May 31, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
Checkmate Pharmaceuticals, Inc. was delisted on May 31, 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.
13F holders, Q2 2022
Institutional positions in Checkmate Pharmaceuticals, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
CMPI is no longer listed, and 13F filings after Q1 2022 list far fewer holders. See Q1 2022
- Institutional holders
- 0
- −26 vs. Q1 2022
- Shares held
- 0
- −17.2M (−100.0%) vs. Q1 2022
- Total value
- $0
- −$54.8M (−100.0%) vs. Q1 2022
- New holders
- 0
- 0 more added
- Sold out
- 26
- 0 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 26 | $54.8M |
| Q4 2021 | 25 | $46.3M |
| Q3 2021 | 32 | $64.5M |
| Q2 2021 | 34 | $97.3M |
| Q1 2021 | 37 | $202.5M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Checkmate Pharmaceuticals, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 0 | $0 | 0.00% | −1,501,716−100.0% | Sold out |
| venBio Partners LLC | 0 | $0 | 0.00% | −3,673,374−100.0% | Sold out |
| Sofinnova Investments, Inc. | 0 | $0 | 0.00% | −3,606,707−100.0% | Sold out |
| Novo Holdings A/S | 0 | $0 | 0.00% | −2,161,990−100.0% | Sold out |
| Omega Fund Management, LLC | 0 | $0 | 0.00% | −1,335,050−100.0% | Sold out |
| Decheng Capital Management III (Cayman), LLC | 0 | $0 | 0.00% | −1,333,254−100.0% | Sold out |
| Clough Capital Partners L P | 0 | $0 | 0.00% | −1,137,764−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −966,226−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −556,423−100.0% | Sold out |
| Sectoral Asset Management Inc | 0 | $0 | 0.00% | −541,765−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −106,500−100.0% | Sold out |
| RBF Capital, LLC | 0 | $0 | 0.00% | −68,034−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −51,334−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −41,466−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −30,636−100.0% | Sold out |
| Cambridge Trust Co | 0 | $0 | 0.00% | −24,609−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −14,553−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −11,424−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −3,005−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,940−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −183−100.0% | Sold out |
| Johnson Midwest Financial, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −49−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −33−100.0% | Sold out |